DE06075704T1 - Vorbeugung und Behandlung von amyloidogener Krankheit - Google Patents

Vorbeugung und Behandlung von amyloidogener Krankheit Download PDF

Info

Publication number
DE06075704T1
DE06075704T1 DE06075704T DE06075704T DE06075704T1 DE 06075704 T1 DE06075704 T1 DE 06075704T1 DE 06075704 T DE06075704 T DE 06075704T DE 06075704 T DE06075704 T DE 06075704T DE 06075704 T1 DE06075704 T1 DE 06075704T1
Authority
DE
Germany
Prior art keywords
pharmaceutical composition
composition according
immunogenic
adjuvant
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE06075704T
Other languages
English (en)
Inventor
Dale B. Burlingame Schenk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuralab Ltd
Original Assignee
Neuralab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26748211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE06075704(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuralab Ltd filed Critical Neuralab Ltd
Publication of DE06075704T1 publication Critical patent/DE06075704T1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Pharmazeutische Zusammensetzung, die einen immunogenen Wirkstoff, der zum Induzieren einer immunogenen Reaktion gegenüber Aβ in einem Patienten wirksam ist, und ein pharmazeutisch verträgliches Adjuvanz umfasst.

Claims (20)

  1. Pharmazeutische Zusammensetzung, die einen immunogenen Wirkstoff, der zum Induzieren einer immunogenen Reaktion gegenüber Aβ in einem Patienten wirksam ist, und ein pharmazeutisch verträgliches Adjuvanz umfasst.
  2. Pharmazeutische Zusammensetzung nach Anspruch 1, wobei der Wirkstoff Aβ ist.
  3. Pharmazeutische Zusammensetzung nach Anspruch 2, wobei Aβ Aβ43, Aβ42, Aβ41, Aβ40 oder Aβ39 ist.
  4. Pharmazeutische Zusammensetzung nach Anspruch 1, wobei der Wirkstoff ein immunogenes Fragment von Aβ ist.
  5. Pharmazeutische Zusammensetzung nach Anspruch 4, wobei das immunogene Aβ-Fragment von der N-terminalen Hälfte von Aβ herrührt.
  6. Pharmazeutische Zusammensetzung nach Anspruch 5, wobei das immunogene Aβ-Fragment Aβ1-5 oder Aβ1-6 ist.
  7. Pharmazeutische Zusammensetzung nach Anspruch 1, wobei der immunogene Wirkstoff Multimere des monomerischen immunogenen Wirkstoffs, der in einem der Ansprüche 4-6 genannt ist, beinhaltet.
  8. Pharmazeutische Zusammensetzung nach einem der Ansprüche 1-7, die eine Dosis von mehr als 10 μg des immunogenen Wirkstoffs umfasst.
  9. Pharmazeutische Zusammensetzung nach einem der Ansprüche 1-8, wobei das Adjuvanz Alaun umfasst.
  10. Pharmazeutische Zusammensetzung nach einem der Ansprüche 1-8, wobei das Adjuvanz 3-de-O-acyliertes Monophosphoryllipid A (MPLTM) umfasst.
  11. Pharmazeutische Zusammensetzung nach einem der Ansprüche 1-8, wobei das Adjuvanz StimulonTM QS-21 umfasst.
  12. Pharmazeutische Zusammensetzung nach einem der vorstehenden Ansprüche, wobei der Wirkstoff eine Komponente eines Partikels ist.
  13. Pharmazeutische Zusammensetzung nach Anspruch 12, wobei das Partikel ein Liposom oder ein Mikropartikel ist und der Wirkstoff in dem Liposom oder Mikropartikel emulgiert oder eingekapselt ist.
  14. Pharmazeutische Zusammensetzung nach Anspruch 12 oder Anspruch 13, wobei das Partikel oder Mikropartikel ein Polylaktid-Polyglykolid-Copolymer (PLPG)-Partikel oder -Mikropartikel ist.
  15. Verwendung des wie in einem der vorstehenden Ansprüche definierten Wirkstoffs bei der Herstellung eines Medikaments zum Verhindern oder Behandeln einer Erkrankung, die mit Amyloidablagerungen von Aβ in dem Gehirn eines Patienten assoziiert ist, wobei das Medikament für die weitere Verabreichung eines Adjuvanz angepasst ist, das eine Immunreaktion gegenüber dem Aβ-Peptid erhöht, wobei das Medikament gegebenenfalls in der Form einer Zusammensetzung vorliegt, bei der das Adjuvanz und der Wirkstoff zusammen verabreicht werden können.
  16. Verwendung nach Anspruch 15, wobei das Verhindern oder Behandeln durch Untersuchen von Antikörperreaktionen gegenüber dem immunogenen Wirkstoff über die Zeit überwacht wird.
  17. Verwendung nach Anspruch 15, wobei das Medikament zum Verabreichen des Adjuvanz vor oder nach dem Wirkstoff angepasst ist.
  18. Verwendung nach einem der Ansprüche 15 bis 17, wobei das Adjuvanz Alaun, MPLTM oder StimulonTM QS-21 ist.
  19. Verwendung nach einem der Ansprüche 15 bis 18, wobei die Erkrankung Alzheimerkrankheit ist.
  20. Verwendung nach Anspruch 15 oder Anspruch 19, wobei der Patient: (a) asymptomatisch und/oder (b) unter 50 ist und/oder (i) vererbte Risikofaktoren, die eine Prädisposition gegenüber Alzheimerkrankheit anzeigen, aufweist oder (ii) keine bekannten Risikofaktoren für Alzheimerkrankheit aufweist.
DE06075704T 1997-12-02 1998-11-30 Vorbeugung und Behandlung von amyloidogener Krankheit Pending DE06075704T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6774097P 1997-12-02 1997-12-02
US67740P 1997-12-02
US8097098P 1998-04-07 1998-04-07
US80970P 1998-04-07

Publications (1)

Publication Number Publication Date
DE06075704T1 true DE06075704T1 (de) 2006-12-28

Family

ID=26748211

Family Applications (7)

Application Number Title Priority Date Filing Date
DE69842082T Expired - Lifetime DE69842082D1 (de) 1997-12-02 1998-11-30 Verhinderung und Behandlung der amyloidogenen Erkrankung
DE69840922T Expired - Lifetime DE69840922D1 (de) 1997-12-02 1998-11-30 Vorbeugung und Behandlung von amyloidogener Krankheit
DE06075479T Pending DE06075479T1 (de) 1997-12-02 1998-11-30 Vorbeugung und Behandlung von amyloidogener Krankheit
DE69840969T Expired - Lifetime DE69840969D1 (de) 1997-12-02 1998-11-30 Vorbeugung und Behandlung von amyloidogener Krankheit
DE69839647T Expired - Lifetime DE69839647D1 (de) 1997-12-02 1998-11-30 Vorbeugung und behandlung von amyloidogener krankheit
DE1033996T Pending DE1033996T1 (de) 1997-12-02 1998-11-30 Vorbeugung und behandlung von amyloidogener krankheit
DE06075704T Pending DE06075704T1 (de) 1997-12-02 1998-11-30 Vorbeugung und Behandlung von amyloidogener Krankheit

Family Applications Before (6)

Application Number Title Priority Date Filing Date
DE69842082T Expired - Lifetime DE69842082D1 (de) 1997-12-02 1998-11-30 Verhinderung und Behandlung der amyloidogenen Erkrankung
DE69840922T Expired - Lifetime DE69840922D1 (de) 1997-12-02 1998-11-30 Vorbeugung und Behandlung von amyloidogener Krankheit
DE06075479T Pending DE06075479T1 (de) 1997-12-02 1998-11-30 Vorbeugung und Behandlung von amyloidogener Krankheit
DE69840969T Expired - Lifetime DE69840969D1 (de) 1997-12-02 1998-11-30 Vorbeugung und Behandlung von amyloidogener Krankheit
DE69839647T Expired - Lifetime DE69839647D1 (de) 1997-12-02 1998-11-30 Vorbeugung und behandlung von amyloidogener krankheit
DE1033996T Pending DE1033996T1 (de) 1997-12-02 1998-11-30 Vorbeugung und behandlung von amyloidogener krankheit

Country Status (38)

Country Link
US (26) US20040171816A1 (de)
EP (5) EP1994937B1 (de)
JP (4) JP4677094B2 (de)
KR (3) KR101248711B1 (de)
CN (1) CN100374151C (de)
AR (1) AR020050A1 (de)
AT (4) ATE399016T1 (de)
AU (1) AU1706199A (de)
BG (1) BG104562A (de)
BR (1) BR9815357A (de)
CA (1) CA2312920C (de)
CO (1) CO4980846A1 (de)
CY (3) CY1108331T1 (de)
CZ (1) CZ303137B6 (de)
DE (7) DE69842082D1 (de)
DK (4) DK2305282T3 (de)
EA (3) EA009283B1 (de)
EE (1) EE05377B1 (de)
ES (4) ES2310017T3 (de)
GE (2) GEP20043319B (de)
HK (2) HK1095265A1 (de)
HR (2) HRP20000443B1 (de)
HU (2) HU228493B1 (de)
ID (1) ID25504A (de)
IL (5) IL136252A0 (de)
IS (1) IS5500A (de)
MY (1) MY134906A (de)
NO (3) NO328865B1 (de)
NZ (1) NZ504569A (de)
PE (1) PE20001383A1 (de)
PL (2) PL202706B1 (de)
PT (4) PT1033996E (de)
SA (1) SA99191269B1 (de)
SG (1) SG111083A1 (de)
SI (4) SI2305282T1 (de)
TR (1) TR200001608T2 (de)
TW (1) TWI239847B (de)
WO (1) WO1999027944A1 (de)

Families Citing this family (293)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0866805A1 (de) 1995-12-12 1998-09-30 Karolinska Innovations AB Peptide, das die KLVFF Sequenz von beta-Amyloid bindet
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US6703015B1 (en) 1999-09-03 2004-03-09 Ramot At Tel-Aviv University Ltd. Filamentous bacteriophage displaying an β-amyloid epitope
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7588766B1 (en) * 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
AU4007599A (en) * 1998-05-21 1999-12-06 University Of Tennessee Research Corporation, The Methods for amyloid removal using anti-amyloid antibodies
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US7060670B1 (en) 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
CZ20013916A3 (cs) 1999-05-13 2002-06-12 American Cyanamid Company Adjuvantní kombinované prostředky
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
AU2008203784B2 (en) * 1999-05-28 2012-01-19 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
AR024558A1 (es) * 1999-06-01 2002-10-16 Neuralab Ltd Composiciones del peptido a-beta y procesos para producir las mismas
AU2005202644B2 (en) * 1999-06-01 2009-03-05 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
EP1409654B1 (de) 1999-06-16 2008-08-20 Boston Biomedical Research Institute Immunologische kontrolle des beta-amyloid gehaltes in vivo
US6919075B1 (en) * 1999-09-03 2005-07-19 Ramot At Tel Aviv University Ltd. Bacteriophage displaying aβ epitopes and method of use
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
US20070135337A2 (en) * 1999-11-29 2007-06-14 Neurochem (International) Limited Vaccine for the Prevention and Treatment of Alzheimer's and Amyloid Related Diseases
EP1752472A3 (de) * 1999-12-08 2007-04-25 Intellect Neurosciences, Inc. Schimärische Amyloid-beta-Peptide
WO2001042306A2 (en) 1999-12-08 2001-06-14 Mindset Biopharmaceuticals (Usa), Inc. Chimeric peptides (short b-cell epitope joined to a t-cell epitope) and their use for immunization
ME00183B (me) * 2000-02-21 2011-02-10 Pharmexa As Novi postupak za deregulaciju amiloida
CZ20022748A3 (cs) 2000-02-21 2004-03-17 Pharmexa A/S Nová metoda regulace obsahu amyloidu
AU4178601A (en) 2000-02-24 2001-09-03 Univ Washington Humanized antibodies that sequester abeta peptide
CA2404237C (en) 2000-04-05 2010-01-26 University Of Tennessee Research Corporation Methods of investigating, diagnosing, and treating amyloidosis
IL152625A0 (en) * 2000-05-22 2003-06-24 Univ New York SYNTHETIC IMMUNOGENIC BUT NON-AMYLOIDOGENIC PEPTIDES HOMOLOGOUS TO AMYLOID beta FOR INDUCTION OF AN IMMUNE RESPONSE TO AMYLOID beta AND AMYLOID DEPOSITS
JP2003516929A (ja) * 2000-06-01 2003-05-20 ニユーララブ・リミテツド アミロイド形成性疾患の予防および治療
EP2263453B1 (de) * 2000-06-20 2018-06-13 The Governing Council Of The University Of Toronto Transgenes Tiermodell für neurodegenerative Erkrankungen
US7371920B2 (en) 2000-06-20 2008-05-13 The Governing Council Of The University Of Toronto Transgenic mouse model of neurodegenerative disorders
ATE376059T1 (de) 2000-06-23 2007-11-15 Wyeth Corp Assemblierung von wildtyp und chimären influenzavirus-ähnlichen partikeln (vlps)
WO2002000245A1 (en) 2000-06-28 2002-01-03 Prana Biotechnology Limited Neurotoxic oligomers
CA2414772C (en) * 2000-07-07 2011-06-28 Jan Naslund Prevention and treatment of alzheimer's disease
AU2007200047B2 (en) * 2000-07-07 2009-11-26 Bioarctic Neuroscience Ab Prevention and treatment of Alzheimer's disease
ATE441663T1 (de) * 2000-09-06 2009-09-15 Aventis Pharma Sa Verfahren und zusammensetzungen für amyloidosis- verbundene krankheiten
AU1225702A (en) * 2000-09-19 2002-04-02 Evotec Neurosciences Gmbh Methods and compounds for treating brain amyloidosis
IL139308A0 (en) * 2000-10-26 2001-11-25 Marikovsky Moshe Peptides from amyloid precursor protein which inhibit tumor growth and metastasis
JP2004523483A (ja) 2000-11-10 2004-08-05 ワイス・ホールデイングス・コーポレーシヨン アジュバントの組合せ製剤
DE60141976D1 (de) 2000-11-29 2010-06-10 Univ Rochester Helfervirus-freie herpesvirus-amplifikatpartikel und deren verwendungen
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
DK1355918T5 (da) 2000-12-28 2012-02-20 Wyeth Llc Rekombinant beskyttelsesprotein af streptococcus pneumoniae
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US6815175B2 (en) 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
WO2002088306A2 (en) 2001-04-30 2002-11-07 Eli Lilly And Company Humanized antibodies
DE60229051D1 (de) 2001-04-30 2008-11-06 Lilly Co Eli Humanisierte antikörper
US8092791B2 (en) 2001-05-23 2012-01-10 University Of Rochester Method of producing herpes simplex virus amplicons, resulting amplicons, and their use
US6906169B2 (en) 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
AU2002322380B2 (en) 2001-06-07 2006-11-02 Government Of The United States Of America As Represented By The Uniformed Services University Of The Health Sciences Mutant forms of cholera holotoxin as an adjuvant
CA2449663A1 (en) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
AU2002312566A1 (en) 2001-07-09 2003-01-29 Elan Pharmaceuticals, Inc. Methods of inhibiting amyloid toxicity
US7829087B2 (en) 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
US20060073149A1 (en) * 2001-08-17 2006-04-06 Bales Kelly R Rapid improvement of cognition in condition related to abeta
CA2457145C (en) * 2001-08-17 2010-12-21 Washington University Assay method for alzheimer's disease
CA2451998A1 (en) * 2001-08-17 2003-02-27 Eli Lilly And Company Anti-a.beta. antibodies
ES2391905T3 (es) 2001-08-17 2012-11-30 Washington University Método de ensayo para la enfermedad de alzheimer
JP2005500389A (ja) * 2001-08-17 2005-01-06 イーライ・リリー・アンド・カンパニー Ａβに関連する病態および疾患を治療するための、可溶性Ａβに高い親和性を有する抗体の使用
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
US20030082191A1 (en) 2001-08-29 2003-05-01 Poduslo Joseph F. Treatment for central nervous system disorders
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP1572894B1 (de) * 2001-11-21 2016-04-13 New York University Zu amyloid-beta, prionprotein, amylin, alpha-synuclein oder polyglutaminwiederholungen homologe synthetische immunogene, jedoch keine ablagerungen bildende polypeptide und peptide zur induzierung einer immunreaktion dagegen
US20040052928A1 (en) 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
US20040001848A1 (en) * 2002-03-01 2004-01-01 Szu-Yi Chou Method of producing disease-specific antigens
IL163812A0 (en) 2002-03-05 2005-12-18 Univ Ramot Immunizing composition and method for inducing an immune response against the -secretase cleavage site of amyloid precursor protein
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20040091945A1 (en) * 2002-07-17 2004-05-13 Cheryl Fitzer-Attas Peptides and methods of screening immunogenic peptide vaccines against Alzheimer's Disease
DE60336902D1 (de) 2002-07-19 2011-06-09 Cytos Biotechnology Ag Impfstoffzusammensetzungen enthaltende amyloid beta 1-6 antigenarrays
WO2004014296A2 (en) * 2002-08-13 2004-02-19 U.S. Department Of Veterans Affairs Method of detecting and preventing alzheimer’s disease, particularly at prodromal and early stages
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
AU2003270643A1 (en) * 2002-09-12 2004-04-30 The Regents Of The University Of California Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
US9535076B2 (en) 2002-09-12 2017-01-03 The Regents Of The University Of California Methods and compositions for eliciting an amyloid-selective immune response
JP2006519762A (ja) * 2002-10-09 2006-08-31 ライナット ニューロサイエンス コーポレイション アミロイドβペプチド及びその組成物に対する抗体を使用して、アルツハイマー病を治療する方法
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US8697082B2 (en) 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
CN100450551C (zh) * 2002-11-29 2009-01-14 中国医学科学院基础医学研究所 用于治疗和预防阿尔茨海默病的重组腺相关病毒基因疫苗及其用途
AU2003303198A1 (en) 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
KR20050118669A (ko) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 가용성 ａ-베타에 대한 항체를 생성하기 위한 능동 면역화
WO2004071408A2 (en) 2003-02-10 2004-08-26 Applied Molecular Evolution, Inc. Aβ BINDING MOLECULES
MXPA05008487A (es) * 2003-02-10 2006-03-10 To Bbb Holding B V Acidos nucleicos expresados en forma diferencial en la barrera hemato-encefalica bajo condiciones de inflamacion.
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
CA2519511A1 (en) * 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
KR100546066B1 (ko) * 2003-03-21 2006-01-26 한국생명공학연구원 베타아밀로이드 유전자의 다중 연결체를 발현하는 형질전환 식물 세포 및 이로부터 배양된 식물
US7632816B2 (en) * 2003-03-28 2009-12-15 New York University Treatment of Alzheimer amyloid deposition
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
ES2246178B1 (es) 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
US7358331B2 (en) * 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
JP4888876B2 (ja) * 2003-06-13 2012-02-29 田平 武 アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター
CN101415724B (zh) 2003-06-30 2015-12-02 特拉维夫大学未来科技开发有限公司 肽、抗肽抗体以及用它们来诊断和治疗淀粉样蛋白相关疾病的方法
WO2005014041A2 (en) * 2003-07-24 2005-02-17 Novartis Ag Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases
US7807171B2 (en) 2003-07-25 2010-10-05 Ac Immune Sa Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
CA2545152A1 (en) * 2003-11-07 2005-05-26 Howard J. Federoff Compositions and methods of treating neurological diseases
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
EP2479184A3 (de) 2003-12-17 2013-09-04 Janssen Alzheimer Immunotherapy Beta-Immunogen-Peptidträgerkonjugate und Herstellungsverfahren dafür
US20050225165A1 (en) * 2004-04-13 2005-10-13 Naik Sanjeev M Brake by-wire control system
AU2005235271A1 (en) 2004-04-26 2005-11-03 Innate Pharma Adjuvant composition and methods for its use
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
SG186686A1 (en) * 2004-06-25 2013-01-30 Id Biomedical Corp Quebec Compositions and methods for treating neurological disorders
US7955812B2 (en) 2004-07-19 2011-06-07 The General Hospital Corporation Methods of diagnosing alzheimer's disease by detecting antibodies to cross-linked β-amyloid oligomers
EA016357B1 (ru) 2004-07-30 2012-04-30 Ринат Ньюросайенс Корп. Антитела, направленные против бета-амилоидного пептида, и способы их применения
EP1787998A4 (de) 2004-08-11 2008-08-27 Mitsubishi Chem Corp Antikörper und deren verwendung
WO2006042158A2 (en) * 2004-10-05 2006-04-20 Wyeth Methods and compositions for improving recombinant protein production
WO2006044666A2 (en) * 2004-10-15 2006-04-27 Northeastern University Detection of disease associated proteolysis by direct mass spectrometry analysis of low molecular weight peptides
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
AR051800A1 (es) * 2004-12-15 2007-02-07 Wyeth Corp Anticuerpos a beta usados en mejorar la cognicion
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
JP2008527005A (ja) * 2005-01-14 2008-07-24 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニア ドルーゼン形成を阻害するため、およびドルーゼン関連障害を診断または治療するための組成物および方法
AU2006208226A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
KR20070107079A (ko) * 2005-01-28 2007-11-06 와이어쓰 안정화된 액체 폴리펩타이드 제형
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
CN101228272A (zh) * 2005-04-20 2008-07-23 生物载体株式会社 用于治疗阿尔茨海默病的具有较高安全性的经鼻腔内给药基因疫苗
CA2605957A1 (en) * 2005-04-20 2006-10-26 Dnavec Corporation Highly safe intranasally administrable gene vaccines for treating alzheimer's disease
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
WO2006119352A2 (en) * 2005-05-03 2006-11-09 University Of South Florida Method of treating cognitive decline and synaptic loss related to alzheimer's disease
CN101171031B (zh) 2005-05-05 2011-09-28 默沙东公司 防止和治疗阿尔茨海默病的肽偶联物组合物和方法
WO2006126682A1 (ja) * 2005-05-27 2006-11-30 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute アルツハイマー病の予防・治療用ワクチン
EP2388274A1 (de) 2005-06-17 2011-11-23 Janssen Alzheimer Immunotherapy Verfahren zur Reinigung von Anti-A-Beta-Antikörpern
AU2006268293B2 (en) 2005-07-10 2011-03-17 Assia Spe, Llc Adaptive margin and band control
WO2007056401A1 (en) * 2005-11-09 2007-05-18 Merck & Co., Inc. Method for identifying modulators of osbp useful for treating alzheimer's disease
US7592427B2 (en) * 2005-11-28 2009-09-22 Zymogenetics, Inc. Antibodies to IL-21 receptor
EP2567973B1 (de) * 2005-11-28 2014-05-14 Zymogenetics, Inc. IL-21-Antagonisten
EP1954718B1 (de) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a-globulomer-antikörper, antigen bindende gruppen davon, entsprechende hybridome, nukleinsäuren, vektoren, wirtszellen, verfahren zur herstellung dieser antikörper, zusammensetzungen, die diese antikörper enthalten, verwendungen dieser antikörper und verfahren zur verwendung dieser antikörper
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
WO2007067512A2 (en) * 2005-12-08 2007-06-14 Merck & Co., Inc. Method for identifying modulators of adprh useful for treating alzheimer's disease
CA2632822C (en) * 2005-12-12 2018-08-28 Ruth Greferath A beta 1-42 specific monoclonal antibodies with therapeutic properties
UA99097C2 (ru) 2005-12-12 2012-07-25 Ф. Хоффманн-Ля Рош Аг Композиция, содержащая антитела к амилоиду бета 4, имеющие гликозилированный вариабельный участок
KR20080103560A (ko) * 2006-02-22 2008-11-27 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 항 아밀로이드-β-펩티드 항체 생산 유도용 펩티드 백신
EP2325209A3 (de) 2006-03-23 2011-08-03 BioArtic Neuroscience AB Verbesserte protofibril selektive Antikörper und deren Verwendung
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US7479550B2 (en) 2006-06-02 2009-01-20 The Board Of Regents Of The University Of Texas System Amyloid β gene vaccines
WO2008011348A2 (en) * 2006-07-14 2008-01-24 Ac Immune S.A. Humanized antibody against amyloid beta
WO2008021296A2 (en) * 2006-08-14 2008-02-21 Thymon, L.L.C. Compositions and methods for the treatment and prophylaxis of alzheimer's disease
US7744890B2 (en) * 2006-10-12 2010-06-29 Wyeth Llc Methods and compositions with reduced opalescence
WO2008070284A2 (en) * 2006-10-16 2008-06-12 Johnnie B. Byrd, Sr. Alzheimer's Center And Research Institute Amyloid beta peptides and methods of uses thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
US20080214987A1 (en) 2006-12-22 2008-09-04 Nanomed Devices, Inc. Microdevice And Method For Transdermal Delivery And Sampling Of Active Substances
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
EA017611B1 (ru) 2007-01-05 2013-01-30 Юнивэсэти Оф Цюрих Способ получения связывающей молекулы, специфичной к белку, ассоциированному с расстройством, или антитела или его связывающего фрагмента или по меньшей мере одной цепи иммуноглобулина, связывающих вышеуказанный белок (варианты), связывающая молекула, антитело, цепь иммуноглобулина или их связывающий фрагмент (варианты), антиген, полинуклеотид, вектор и клетка-хозяин, их включающие композиция и набор и способ диагностики или лечения неврологических расстройств посредством
WO2008084402A2 (en) 2007-01-11 2008-07-17 Philipps-Universitaet Marburg Diagnosis and treatment of alzheimer's and other neurodementing diseases
KR101160385B1 (ko) 2007-01-18 2012-07-10 일라이 릴리 앤드 캄파니 페길화된 Ａβ ＦＡＢ
CA2678963C (en) 2007-02-23 2018-05-01 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic and amyloidogenic disease
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
US7618944B2 (en) * 2007-03-01 2009-11-17 Intezyne Technologies, Inc. Encapsulated amyloid-beta peptides
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
KR20100016661A (ko) * 2007-04-18 2010-02-12 얀센 알츠하이머 이뮤노테라피 대뇌 아밀로이드 혈관병증의 예방 및 치료
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
EP2012122A1 (de) * 2007-07-06 2009-01-07 Medigene AG Strukturproteine von mutierten Parvoviren als Impfstoffe
JP2010528583A (ja) * 2007-06-11 2010-08-26 エーシー イミューン ソシエテ アノニム アミロイドβに対するヒト化抗体
CN101820911B (zh) * 2007-06-12 2015-05-06 Ac免疫有限公司 β淀粉样蛋白的人源化抗体
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
JP2010531878A (ja) 2007-06-27 2010-09-30 マリン ポリマー テクノロジーズ，インコーポレーテッド ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用
EP2182983B1 (de) 2007-07-27 2014-05-21 Janssen Alzheimer Immunotherapy Behandlung von amyloidogenen erkrankungen mittels humanisierter anti-abeta antikörper
CN106310293A (zh) 2007-09-27 2017-01-11 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
SG178809A1 (en) * 2007-10-05 2012-03-29 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
BRPI0818621A8 (pt) * 2007-10-05 2018-01-30 Ac Immune Sa composição farmacêutica, e, métodos para reduzir a carga da placa e a quantidade de placas na camada de célula de gânglio retinal de um indivíduo, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular, para diagnosticar uma doença ocular e uma predisposição a uma doença ocular, para monitorar doença ocular, para predizer responsividade de um paciente, e para reter ou diminuir pressão ocular nos olhos de um indivíduo
WO2009048539A2 (en) 2007-10-05 2009-04-16 Genentech, Inc. Monoclonal antibody
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US8445649B2 (en) * 2007-10-29 2013-05-21 Tao Health Life Pharma Co., Ltd. Antibody and use thereof
KR101615215B1 (ko) 2007-12-07 2016-04-25 지모제넥틱스, 인코포레이티드 항-사람 ｉｌ-21 단클론성 항체
WO2009085200A2 (en) 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
US9345753B2 (en) * 2008-01-16 2016-05-24 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Vaccine for alzheimer's disease
ES2524699T3 (es) * 2008-06-05 2014-12-11 Immunovaccine Technologies Inc. Composiciones que comprenden liposomas, un antígeno, un polinucleótido y un vehículo que comprende una fase continua de una sustancia hidrófoba
US20110171259A1 (en) * 2008-09-05 2011-07-14 Martin Gagne Novel Compositions and Adjuvants
US20110263450A1 (en) * 2008-09-26 2011-10-27 The University Of Melbourne Alzheimer's disease biomarkers
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US20120087940A1 (en) * 2008-10-31 2012-04-12 Dnavec Corporation Vector for treating alzheimer's disease
CN102203122A (zh) 2008-11-05 2011-09-28 惠氏有限责任公司 用于预防β-溶血链球菌(BHS)疾病的多组分免疫原性组合物
EP3521309A1 (de) 2008-12-19 2019-08-07 Biogen International Neuroscience GmbH Menschliche anti-alpha-synuclein-antikörper
US8614297B2 (en) 2008-12-22 2013-12-24 Hoffmann-La Roche Inc. Anti-idiotype antibody against an antibody against the amyloid β peptide
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
AU2010221418B2 (en) 2009-03-02 2015-06-04 Dignity Health Diagnostic devices and methods of use
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
EP2464661B1 (de) 2009-08-13 2018-01-17 The Johns Hopkins University Verfahren zur modulierung der immunfunktion mittles anti-b7-h7cr antikörper
US9125846B2 (en) 2010-10-15 2015-09-08 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
CA2772488C (en) 2009-09-11 2018-04-17 Probiodrug Ag Heterocyclic derivatives as inhibitors of glutaminyl cyclase
US9757398B2 (en) 2010-02-20 2017-09-12 Euroespes Biotecnnologia, S.L. Prevention and treatment of alzheimer's disease by amyloid beta peptide and sphin-gosine-1-phosphate
SG183854A1 (en) * 2010-03-03 2012-10-30 Univ British Columbia Oligomer-specific amyloid beta epitope and antibodies
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
BR112012022102A2 (pt) 2010-03-03 2017-01-10 Boehringer Ingelheim Int polipeptídeos de ligação a a-beta.
US8269019B2 (en) 2010-03-10 2012-09-18 Probiodrug Ag Inhibitors
JP2013523182A (ja) 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
EP2560953B1 (de) 2010-04-21 2016-01-06 Probiodrug AG Hemmer der glutaminylzyklase
WO2011151076A2 (en) 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
US9289488B2 (en) 2010-08-12 2016-03-22 Ac Immune Sa Vaccine engineering
EP2603524A1 (de) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta-bindende proteine
HUE052850T2 (hu) 2010-08-23 2021-05-28 Wyeth Llc Neisseria meningitidis RLP2086 antigéneket tartalmazó stabil készítmények
ES2585328T5 (es) 2010-09-10 2022-12-14 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
US9687447B2 (en) 2010-10-26 2017-06-27 Ac Immune S.A. Method for preparing liposome-based constructs
AR083885A1 (es) 2010-11-15 2013-03-27 Univ Ramot Analogos de dipeptidos para el tratamiento de afecciones asociadas con la formacion de fibrillas amiloides
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
RU2473133C2 (ru) * 2011-03-30 2013-01-20 Государственное образовательное учреждение высшего профессионального образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения и социального развития РФ Способ профилактики системного амилоидоза и его нефропатической формы у экспериментальных животных
JP5767393B2 (ja) 2011-03-31 2015-08-19 ファイザー・インク 新規二環式ピリジノン
US9512185B2 (en) 2011-06-01 2016-12-06 Xiamen University Fusion protein comprising diphtheria toxin non-toxic mutant CRM197 or fragment thereof
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
TR201815563T4 (tr) 2011-06-23 2018-11-21 Biogen Int Neuroscience Gmbh Anti-alfa sinüklein bağlayıcı moleküller.
WO2013012811A2 (en) 2011-07-19 2013-01-24 New York University Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
WO2013013056A1 (en) 2011-07-19 2013-01-24 New York University Method for treating amyloid disease
CN102895659B (zh) * 2011-07-29 2014-10-29 复旦大学 一种防治老年痴呆症复合疫苗及其制备方法
US20150065449A1 (en) 2011-08-12 2015-03-05 Florida State University Research Foundation, Inc. Treating Amyloidoses With A Vitamin B12 Composition Including Melatonin, Resveratrol, and EGCG
US20150065448A1 (en) * 2011-08-12 2015-03-05 The Florida State University Research Foundation Inc. Methods of treating amyloidoses with vitamin b12 and diagnostic test for detecting the presence of amyloid-beta peptides
JP6043355B2 (ja) 2011-08-31 2016-12-14 ファイザー・インク ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
RS53496B1 (en) 2011-10-04 2015-02-27 Affiris Ag PROCEDURE FOR THE DETECTION OF Aβ-SPECIFIC ANTIBODIES IN A BIOLOGICAL SAMPLE
US20140294724A1 (en) * 2011-10-24 2014-10-02 Intellect Neurosciences, Inc. Compositions and methods for treatment of proteinopathies
JP2012102131A (ja) * 2012-01-05 2012-05-31 Elan Pharma Internatl Ltd アミロイド形成性疾患の予防および治療
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY167723A (en) 2012-03-09 2018-09-21 Pfizer Neisseria meningitidis compositions and methods thereof
JP6110937B2 (ja) 2012-05-04 2017-04-05 ファイザー・インク ＡＰＰ、ＢＡＣＥ１、およびＢＡＣＥ２の阻害剤としての複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
SG11201408044QA (en) 2012-06-29 2015-01-29 Pfizer NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
US9260455B2 (en) 2012-09-20 2016-02-16 Pfizer Inc. Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
US9855276B2 (en) 2012-10-25 2018-01-02 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US9414752B2 (en) 2012-11-09 2016-08-16 Elwha Llc Embolism deflector
WO2014091352A1 (en) 2012-12-11 2014-06-19 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
CA2893333C (en) 2012-12-19 2017-10-24 Pfizer Inc. Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014107731A1 (en) 2013-01-07 2014-07-10 Biomedical Research Models, Inc. Therapeutic vaccines for treating herpes simplex virus type 2 infections
JP2016507551A (ja) 2013-02-13 2016-03-10 ファイザー・インク ヘテロアリール置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
BR112015019276A2 (pt) 2013-02-19 2017-07-18 Pfizer compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
WO2014159614A1 (en) * 2013-03-14 2014-10-02 Flow Pharma, Inc. Adjuvant and antigen particle formulation
US9102752B2 (en) 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
EP2787347A1 (de) 2013-04-03 2014-10-08 Affiris AG Verfahren zur Erkennung von Aß-spezifischen Antikörpern in einer biologischen Probe
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
WO2015017280A1 (en) 2013-07-28 2015-02-05 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
ES2742078T3 (es) 2013-10-04 2020-02-13 Pfizer Piridonas bicíclicas novedosas como moduladores de gamma-secretasa
CN110305095A (zh) 2013-10-22 2019-10-08 综合医院公司 色甘酸衍生物以及成像和治疗的相关方法
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
MD20160102A2 (ro) 2014-04-01 2017-04-30 Pfizer Inc. Cromen şi 1,1a,2,7b-tetrahidrociclopropa[c]cromen piridopirazindione ca modulatori ai gama-secretazei
MX2016013329A (es) 2014-04-10 2017-01-26 Pfizer 2-amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8h )-il-1,3-tiazol-4-ilamidas.
CN106535924A (zh) 2014-04-29 2017-03-22 阿费里斯股份公司 阿尔茨海默病(ad)的治疗和预防
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
ES2651537T3 (es) * 2014-04-29 2018-01-29 Affiris Ag Tratamiento y prevención de la enfermedad de Alzheimer (AD)
JP2017515812A (ja) 2014-04-29 2017-06-15 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ アルツハイマー病（ａｄ）の処置および予防
WO2015165971A1 (en) * 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
US10047166B2 (en) * 2014-06-17 2018-08-14 Academia Sinica Humanized anti-IgE antibodies that crosslink CD23 on B lymphocytes but do not sensitize mast cells
SI3166970T1 (sl) 2014-07-10 2021-09-30 Bioarctic Ab Izboljšana A-beta protofibril vezavna protitelesa
US10131669B2 (en) 2014-07-24 2018-11-20 Pfizer Inc. Pyrazolopyrimidine compounds
PL3177624T3 (pl) 2014-08-06 2019-09-30 Pfizer Inc. Związki imidazopirydazynowe
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
BR112017015693A2 (pt) 2015-02-03 2018-03-20 Pfizer ciclopropabenzofuranil piridopirazinadionas
BR112017017460A2 (pt) 2015-02-19 2018-04-10 Pfizer Inc. composições de neisseria meningitidis e métodos das mesmas
HUE051898T2 (hu) 2015-06-17 2021-03-29 Pfizer Triciklusos vegyületek és alkalmazásuk foszfodiészteráz inhibitorokként
LT3313879T (lt) 2015-06-24 2022-03-25 F. Hoffmann-La Roche Ag Antikūnai prieš transferino receptorių su pritaikytu giminingumu
AU2016322813B2 (en) 2015-09-14 2021-04-01 Pfizer Inc. Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors
AU2016325665A1 (en) 2015-09-24 2018-03-08 Pfizer Inc. N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
EP3353174A1 (de) 2015-09-24 2018-08-01 Pfizer Inc N-[2-(3-amino-2,5-dimethyl-1,1-dioxid-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)]-1,3-thiazol-4-yl-amide als bace-hemmer
EP3353182A1 (de) 2015-09-24 2018-08-01 Pfizer Inc Tetrahydropyrano[3,4-d][1,3]oxazin-derivate und deren verwendung als bace-inhibitoren
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
NZ741067A (en) 2015-10-02 2023-07-28 Hoffmann La Roche Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
CA3004482A1 (en) 2015-11-09 2017-05-18 Neil R. Cashman N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
CN108350052A (zh) * 2015-11-09 2018-07-31 英属哥伦比亚大学 淀粉样蛋白β中间区域中的表位及其构象选择性抗体
CA3004498A1 (en) * 2015-11-09 2017-05-18 Neil R. Cashman Amyloid beta epitopes and antibodies thereto
US10323042B2 (en) 2016-02-23 2019-06-18 Pfizer Inc. 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
ES2878160T3 (es) 2016-07-01 2021-11-18 Pfizer Derivados de 5,7-dihidro-pirrolo-piridina para el tratamiento de enfermedades neurológicas y neurodegenerativas
AU2017321782B2 (en) 2016-08-31 2022-03-10 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2018230109B2 (en) 2017-03-10 2022-05-12 Pfizer Inc. Cyclic substituted imidazo[4,5-c]quinoline derivatives
JP7219223B2 (ja) 2017-03-10 2023-02-07 ファイザー・インク ＬＲＲＫ２阻害剤としての新規のイミダゾ［４，５－ｃ］キノリン誘導体
RU2678987C2 (ru) 2017-04-28 2019-02-05 Общество с ограниченной ответственностью "Научно-производственная фирма ВЕРТА" Пептид для лечения болезни альцгеймера
US20230137562A1 (en) 2017-06-07 2023-05-04 Adrx, Inc. Tau aggregation inhibitors
JP7263266B2 (ja) 2017-06-22 2023-04-24 ファイザー・インク ジヒドロ－ピロロ－ピリジン誘導体
US11209638B2 (en) * 2017-07-05 2021-12-28 West Virginia University Systems and methods for supporting and positioning body tissue samples in a microscope
MX2020000577A (es) 2017-07-20 2020-09-10 Aztherapies Inc Formulaciones en polvo de cromolina sodica e ibuprofeno.
US11453701B2 (en) 2017-08-18 2022-09-27 Adrx, Inc. Tau aggregation peptide inhibitors
CA3073066A1 (en) 2017-08-22 2019-02-28 Biogen Ma Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
PT3768669T (pt) 2018-03-23 2023-04-24 Pfizer Derivados de piperazina azaspiro
EP3817739A4 (de) 2018-07-02 2022-04-13 The General Hospital Corporation Pulverförmige formulierungen aus cromolyn-natrium und alpha-lactose
JP2023526500A (ja) 2020-05-19 2023-06-21 オター プロシーナ リミテッド アルツハイマー病の処置のためのマルチエピトープワクチン

Family Cites Families (433)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US589566A (en) * 1897-09-07 meevten
US6096318A (en) 1973-05-07 2000-08-01 The Ohio State University Antigenically modified HCG polypeptides
JPS57212347A (en) * 1981-06-25 1982-12-27 Nissan Motor Co Ltd Air-fuel ratio control system
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5158769A (en) 1984-03-07 1992-10-27 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
US5417986A (en) 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
IT1190383B (it) * 1985-08-01 1988-02-16 Eniricerche Spa Sostanze peptidominetiche ad azione ipotensiva
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US4713366A (en) * 1985-12-04 1987-12-15 The Ohio State University Research Foundation Antigenic modification of polypeptides
US5096706A (en) * 1986-03-25 1992-03-17 National Research Development Corporation Antigen-based treatment for adiposity
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5278049A (en) * 1986-06-03 1994-01-11 Incyte Pharmaceuticals, Inc. Recombinant molecule encoding human protease nexin
US5231170A (en) * 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
US5220013A (en) * 1986-11-17 1993-06-15 Scios Nova Inc. DNA sequence useful for the detection of Alzheimer's disease
US5187153A (en) 1986-11-17 1993-02-16 Scios Nova Inc. Methods of treatment using Alzheimer's amyloid polypeptide derivatives
US5223482A (en) 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US4879213A (en) 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US4818397A (en) * 1986-12-22 1989-04-04 Sundstrand Corporation Shut-off valve seal
DE3702789A1 (de) 1987-01-30 1988-08-18 Bayer Ag Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins
US4912206A (en) * 1987-02-26 1990-03-27 The United States Of America As Represented By The Department Of Health And Human Services CDNA clone encoding brain amyloid of alzheimer's disease
EP0307434B2 (de) * 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Geänderte antikörper
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5583112A (en) * 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5245015A (en) 1991-04-26 1993-09-14 Tanox Biosystems, Inc. Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
DE3854741T3 (de) 1987-06-24 2002-08-14 Autoimmune Inc Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen.
US5641474A (en) * 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
US5571499A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5571500A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5645820A (en) * 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5869054A (en) * 1987-06-24 1999-02-09 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of autoantigens
US4912208A (en) * 1987-06-29 1990-03-27 Abbott Laboratories Fluorophores for encapsulation into liposomes
US5004697A (en) * 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US4966753A (en) 1987-08-18 1990-10-30 Molecular Rx, Inc. Immunotherapeutic methods and compositions employing antigens characteristic of malignant neoplasms
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5231000A (en) * 1987-10-08 1993-07-27 The Mclean Hospital Antibodies to A4 amyloid peptide
CA1339014C (en) 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
JP2518911B2 (ja) 1987-10-23 1996-07-31 森永乳業株式会社 ｃ―ｆｍｓ癌原遺伝子の過剰発現によって特徴づけられた癌の処置用組成物および方法
US5089603A (en) * 1989-06-21 1992-02-18 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted iga
WO1989006689A1 (en) 1988-01-13 1989-07-27 The Mclean Hospital Corporation Genetic constructs containing the alzheimer brain amyloid gene
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5576184A (en) * 1988-09-06 1996-11-19 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
US5098706A (en) * 1988-11-01 1992-03-24 The Regents Of The University Of California Juvenile hormone esterase for insect control
WO1990005142A1 (en) 1988-11-10 1990-05-17 Imperial Cancer Research Technology Ltd. Polypeptides
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5227159A (en) * 1989-01-31 1993-07-13 Miller Richard A Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies
US5262332A (en) 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
WO1990012871A1 (en) 1989-04-14 1990-11-01 Research Foundation For Mental Hygiene, Inc. Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10
AU5525090A (en) 1989-04-14 1990-11-16 Research Foundation For Mental Hygiene, Inc. Monoclonal antibody to amyloid peptide
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
DE69033487T2 (de) 1989-12-20 2000-06-29 Autoimmune Inc Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1690935A3 (de) 1990-01-12 2008-07-30 Abgenix, Inc. Bildung von xenogenen Antikörpern
JPH05508621A (ja) 1990-03-02 1993-12-02 オートイミューン　インク 自己抗原の経口投与による自己免疫疾患のダウンコントロール
GB9005705D0 (en) 1990-03-14 1990-05-09 Health Lab Service Board Particle manipulation
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
EP0451700A1 (de) 1990-04-10 1991-10-16 Miles Inc. Rekombinante APP Minigene zur Expression in Transgen-Mäusen als Alzheimer-Krankheitsmuster
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
CA2079880A1 (en) * 1990-04-24 1991-10-25 William E. Van Nostrand Purification, detection and methods of use of protease nexin-2
US5753624A (en) * 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
ATE153534T1 (de) * 1990-04-27 1997-06-15 John Mcmichael Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0600866B1 (de) 1990-06-01 1997-12-03 Chiron Corporation Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit
CA2085127C (en) * 1990-06-15 2002-12-10 Barbara Cordell Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease
US5914109A (en) * 1990-06-15 1999-06-22 New York University Heterohybridomas producing human monoclonal antibodies to HIV-1
WO1991019795A1 (en) 1990-06-19 1991-12-26 Immuvax Nonpathogenic variant virus
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
KR970005049B1 (ko) * 1990-07-16 1997-04-11 더 리젠츠 오브 더 유니벌시티 오브 캘리포니아 바쿨로비루스 발현 시스템, 이 벡터 시스템을 포함하는 이종성 무척추동물 숙주세포, 상기 시스템에 의해 생산되는 가용성의 정제된 야생형 망막아세포종 폴리펩티드 및 이 폴리펩티드의 생산 방법
US5780587A (en) * 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
NZ239643A (en) 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5702906A (en) 1990-09-25 1997-12-30 Genentech, Inc. Antibodies to neurotrophic factor-4 (NT-4)
JPH06502071A (ja) 1990-09-28 1994-03-10 ジ・アップジョン・カンパニー アルツハイマーのアミロイド前駆遺伝子を有するトランスジェニック動物
ATE175118T1 (de) 1990-10-05 1999-01-15 Medarex Inc Gezielte immunostimulierung mit bispezifischen stoffen
IL99754A (en) 1990-10-15 1996-08-04 Autoimmune Inc Pharmaceutical preparation containing autoantib or particle or analogue for the treatment of autoimmune arthritis and multiple sclerosis
GB9023352D0 (en) 1990-10-26 1990-12-05 Lynxvale Ltd Vaccinia vectors,vaccinia genes and expression products thereof
US5877015A (en) 1991-01-21 1999-03-02 Imperial College Of Science, Technology Of Medicine APP770 mutant in alzheimer's disease
EP0501882B1 (de) 1991-03-01 2000-07-12 Merial Verfahren zur Immunoneutralisierung von nichtkastrierten männlichen Haustieren gegen LMRH und Peptide dafür
DE4107857A1 (de) * 1991-03-12 1992-09-17 Thomae Gmbh Dr K Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5192753A (en) * 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
JPH06500128A (ja) 1991-05-08 1994-01-06 シュバイツ・ゼルム―・ウント・インプフィンスティテュート・ベルン 免疫刺激及び免疫増強性再構成インフルエンザウイロソーム及びそれを含有するワクチン
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
LU91067I2 (fr) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US5672805A (en) 1991-07-18 1997-09-30 The Regents Of The University Of California Transgenic mice expressing the neurotoxic C-terminus of β-amyloid precursor protein
US5434050A (en) 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
DK0604552T3 (da) 1991-09-18 1997-08-04 Affymax Tech Nv Fremgangsmåde til syntese af forskellige samlinger af oligomerer
US5837268A (en) 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
WO1993014200A1 (en) 1992-01-07 1993-07-22 Tsi Corporation Transgenic animal models for alzheimer's disease
US5679348A (en) * 1992-02-03 1997-10-21 Cedars-Sinai Medical Center Immunotherapy for recurrent HSV infections
EP1958646A1 (de) 1992-02-11 2008-08-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Immunogenes Dualträgerkonstrukt
US5314813A (en) 1992-02-19 1994-05-24 Scripps Research Institute Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
DK0627933T3 (da) 1992-02-28 2003-03-24 Autoimmune Inc Bystander-suppression af autoimmune sygdomme
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
EP0561087B1 (de) 1992-03-20 1999-08-04 N.V. Innogenetics S.A. Mutierte Form von dem Beta-Amyloidprecursor Proteine Gen
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5851787A (en) * 1992-04-20 1998-12-22 The General Hospital Corporation Nucleic acid encoding amyloid precursor-like protein and uses thereof
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
GB9209118D0 (en) 1992-04-28 1992-06-10 Sb 120 Amsterdam Bv Vaccine compositions
WO1993025210A1 (en) * 1992-06-18 1993-12-23 President And Fellows Of Harvard College Diphtheria toxin vaccines
SG49909A1 (en) * 1992-06-25 1998-06-15 Smithkline Beecham Biolog Vaccine composition containing adjuvants
US5837672A (en) * 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
WO1994001772A1 (en) 1992-07-13 1994-01-20 The Children's Medical Center Corporation SCREEN FOR ALZHEIMER'S DISEASE THERAPEUTICS BASED ON β-AMYLOID PRODUCTION
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
DE69322645T2 (de) 1992-07-31 1999-05-20 Medeva Holdings Bv Expression rekombinanter fusionsproteine in attenuierten bakterien
HUT71860A (en) 1992-08-27 1996-02-28 Deakin Res Ltd Retro-, inverso-, and retro-inverso synthetic peptide analogues
FI96267C (sv) 1992-09-16 1996-06-10 Formit Foodprocessing Ab Oy Vals och maskin för skalning eller formning av potatis och liknande produkter
US5958883A (en) * 1992-09-23 1999-09-28 Board Of Regents Of The University Of Washington Office Of Technology Animal models of human amyloidoses
EP0591042B1 (de) * 1992-09-29 1997-05-28 Nippon Telegraph And Telephone Corporation Multi/Demultiplexer mit Gitter aus gruppierten Wellenleitern und zurückgefürten optischen Wegen
PT665897E (pt) 1992-10-01 2003-11-28 Trustees Of Columbia U In The Bibliotecas quimicas combinatorias complexas codificadas com etiquetas
AU5358494A (en) 1992-10-13 1994-05-09 Duke University Method of inhibiting binding of amyloid precursor protein to beta-amyloid protein
US5605811A (en) * 1992-10-26 1997-02-25 Athena Neurosciences, Inc. Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
EP1298436B1 (de) 1992-10-26 2010-07-14 Elan Pharmaceuticals, Inc. Verfahren zur Identifizierung von Hemmstoffverbindungen der Freisetzung von Beta-Amyloidpeptid (BAP)
US5972336A (en) * 1992-11-03 1999-10-26 Oravax Merieux Co. Urease-based vaccine against helicobacter infection
US5733647A (en) * 1992-11-05 1998-03-31 Polymer Innovations, Inc. Insole
US6210671B1 (en) * 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US5674703A (en) 1992-12-02 1997-10-07 Woo; Savio L. C. Episomal vector systems and related methods
ATE372783T1 (de) 1993-01-22 2007-09-15 Sloan Kettering Inst Cancer Gangliosid-klh-konjugatimpfstoffe mit qs-21 zur verzögerung des wiederauftretens eines melanoms
US5955317A (en) * 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
EP0683234B2 (de) * 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
US5750106A (en) * 1993-01-28 1998-05-12 Novartis Ag Human monoclonal antibodies to cytomegalovirus
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5989565A (en) * 1993-01-29 1999-11-23 University Of Pittsburgh Elution and identification of T cell epitopes from viable cells
US5472693A (en) * 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
DE614989T1 (de) * 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
CA2115900A1 (en) 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
DE69435075T2 (de) 1993-03-17 2009-02-19 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
JP3880063B2 (ja) * 1993-03-18 2007-02-14 シティミューン サイエンシーズ，インコーポレイテッド 生物学的に活性な因子の毒性を低減させる組成物および方法
CN1087176C (zh) * 1993-03-23 2002-07-10 史密斯克莱·比奇曼生物公司 含有3－o脱酰基单磷酰脂a的疫苗制剂
NO940913L (no) * 1993-03-26 1994-09-27 Bristol Myers Squibb Co Preparater for kontrollert frigivelse av biologisk aktiv TGF-
IT1270939B (it) 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
EP0705109B2 (de) * 1993-05-25 2004-01-02 American Cyanamid Company Adjuvantien für impfstoffe gegen das respiratorische synzitialvirus
WO1994028412A1 (en) 1993-05-28 1994-12-08 The Miriam Hospital Composition and method for in vivo imaging of amyloid deposits
ATE212378T1 (de) 1993-06-04 2002-02-15 Whitehead Biomedical Inst Stressproteine und ihre verwendung
US5464823A (en) * 1993-07-20 1995-11-07 The Regents Of The University Of California Mammalian antibiotic peptides
EP0712442B1 (de) 1993-07-30 2002-03-27 Medeva Holdings B.V. Rekombinante tetc-fusionsprotein enthaltene impfstoffzusammensetzungen
EP0664814A1 (de) 1993-08-18 1995-08-02 MorphoSys AG Lipopolysaccharidbindende und neutralisierende peptide
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
AU707083B2 (en) 1993-08-26 1999-07-01 Bavarian Nordic Inc. Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes
CA2169635C (en) 1993-08-26 2002-11-12 Dennis A. Carson Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides
FR2709247B1 (fr) * 1993-08-27 1995-09-29 Martin Jean Raymond Dispositif d'ancrage d'une instrumentation rachidienne sur une vertèbre.
WO1995006407A1 (en) 1993-08-30 1995-03-09 The Regents Of The University Of California Novel component of amyloid in alzheimer's disease and methods for use of same
ES2236693T3 (es) 1993-09-07 2005-07-16 Smithkline Beecham Corporation Anticuerpos recombinantes contra il4 utiles en el tratamiento de afecciones mediadas por il4.
US5652334A (en) * 1993-09-08 1997-07-29 City Of Hope Method for design of substances that enhance memory and improve the quality of life
US5385887A (en) * 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
DE69435171D1 (de) 1993-09-14 2009-01-08 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
US5415584A (en) 1993-09-21 1995-05-16 Tomco2 Equipment Company Particle blast cleaning apparatus
US5470951A (en) 1993-09-29 1995-11-28 City Of Hope Peptides for antagonizing the effects of amyloid βprotein
US5858981A (en) * 1993-09-30 1999-01-12 University Of Pennsylvania Method of inhibiting phagocytosis
JPH09506170A (ja) 1993-10-20 1997-06-17 デューク・ユニヴァーシティ β‐アミロイドペプチドに物質を結合する方法
AU7979094A (en) 1993-10-22 1995-05-08 Genentech Inc. Methods and compositions for microencapsulation of adjuvants
NZ276860A (en) 1993-11-02 1997-09-22 Affymax Tech Nv Apparatus and its use for synthesising diverse molecular products on substrates
US5744368A (en) * 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5434170A (en) * 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP0742831B1 (de) * 1994-01-27 2004-09-29 The Regents Of The University Of Minnesota Nicht humane, transgenische säugetiere mit sich entwickelnder neurologischer krankheit
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
WO1995020979A1 (en) * 1994-02-03 1995-08-10 The Picower Institute For Medical Research Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
AUPM411994A0 (en) 1994-02-25 1994-03-24 Deakin Research Limited Epitopes
WO1995023186A1 (fr) 1994-02-28 1995-08-31 Sumitomo Chemical Company, Limited Composition pour resine polyolefinique et pellicule de resine
US5795954A (en) 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
US6270757B1 (en) 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
CA2189634A1 (en) 1994-05-06 1995-11-16 John J. Baldwin Combinatorial dihydrobenzopyran library
JP3064013B2 (ja) * 1994-05-25 2000-07-12 ジョン マクマイケル， 斑形成疾患の治療のための方法及び材料
US5622701A (en) * 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US5663046A (en) 1994-06-22 1997-09-02 Pharmacopeia, Inc. Synthesis of combinatorial libraries
US5798100A (en) * 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
US6417178B1 (en) * 1994-07-19 2002-07-09 University Of Pittsburgh Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits
WO1996003144A1 (en) 1994-07-27 1996-02-08 The Council Of The Queensland Institute Of Medical Research Polyepitope vaccines
WO1996008565A2 (en) 1994-09-16 1996-03-21 Cancer Research Fund Of Contra Costa RECOMBINANT PEPTIDES DERIVED FROM THE Mc3 ANTI-BA46 ANTIBODY, METHODS OF USE THEREOF, AND METHODS OF HUMANIZING ANTIBODY PEPTIDES
ATE178104T1 (de) * 1994-10-14 1999-04-15 Oriental Sangyo Co Ltd Elektrolytische vorrichtung zur herstellung von kohlenstoff-dioxyd
NL9401735A (nl) * 1994-10-19 1996-06-03 Crown Gear Bv Tandwieloverbrenging van een cilindrisch rondsel met een kroonwiel, het kroonwiel dat toegepast wordt in deze tandwieloverbrenging, een werkwijze volgens welke het kroonwiel gemaakt kan worden alsmede een gereedschap waarmee het kroonwiel gemaakt kan worden.
US5872005A (en) * 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
JPH08137927A (ja) * 1994-11-07 1996-05-31 Hitachi Ltd 部品配置配線表示方法
US6114133A (en) * 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5589154A (en) 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US5688651A (en) 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
EP0820299B1 (de) * 1995-02-06 2002-04-24 Genetics Institute, Inc. Arzneimittelformulierungen für il-12
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US5624937A (en) 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
US5817626A (en) * 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US5854215A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
US6303567B1 (en) * 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids
ES2175083T3 (es) * 1995-03-14 2002-11-16 Praecis Pharm Inc Moduladores de la agregacion de amiloides.
EP0871755A1 (de) * 1995-03-23 1998-10-21 Cantab Pharmaceuticals Research Limited Vektoren zur verabreichung von genen
US5869046A (en) * 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CA2222055A1 (en) 1995-05-23 1996-11-28 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Multimeric proteins
WO1996039176A1 (en) 1995-06-05 1996-12-12 Brigham & Women's Hospital USE OF ORAL TOLERANCE TO SUPPRESS BOTH Th1 AND Th2 IMMUNE RESPONSES AND TO SUPPRESS ANTIBODY PRODUCTION
CA2221986A1 (en) 1995-06-07 1996-12-19 Athena Neurosciences, Inc. Method for identifying alzheimer's disease therapeutics using transgenic animal models
US5948763A (en) 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
IT1276680B1 (it) * 1995-06-08 1997-11-03 Oris Spa Processo di sintesi dell'1-piridiniopropan-3-solfonato
US5910427A (en) 1995-06-22 1999-06-08 La Jolla Institute For Allergy And Immunology Antigen non-specific glycosylation inhibiting factor derivatives
US5780361A (en) * 1995-06-23 1998-07-14 Nec Corporation Salicide process for selectively forming a monocobalt disilicide film on a silicon region
PT750907E (pt) * 1995-06-30 2002-08-30 American Cyanamid Co Formulacoes de vacinas estaveis para administracao parenterica metodo para a sua utilizacao e processo para a sua preparacao
ATE305039T1 (de) * 1995-07-07 2005-10-15 Darwin Molecular Corp Auf chromosom 1 lokalisiertes gen dessen genprodukt mit der alzheimerschen krankheit assoziiert ist.
AUPN443995A0 (en) 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
US5824322A (en) * 1995-08-21 1998-10-20 Cytrx Corporation Compositions and methods for growth promotion
DE69632056T2 (de) * 1995-09-14 2004-12-30 The Regents Of The University Of California, Oakland Für natives prp-sc spezifische antikörper
US5664823A (en) * 1995-09-18 1997-09-09 Ford Global Technologies, Inc. Instrument panel brace
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
WO1997013855A1 (en) 1995-10-10 1997-04-17 Novartis Ag Melanoma-associated protein
US5985242A (en) * 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US5750361A (en) * 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
EP0859959B1 (de) 1995-11-10 2003-08-06 ELAN CORPORATION, Plc Peptide, die den transport über gewebe erhöhen und verfahren zu ihrer identifizierung und verwendung
WO1997018855A1 (en) 1995-11-21 1997-05-29 Eduard Naumovich Lerner Device for enhanced delivery of biologically active substances and compounds in an organism
EP0866805A1 (de) 1995-12-12 1998-09-30 Karolinska Innovations AB Peptide, das die KLVFF Sequenz von beta-Amyloid bindet
JPH09178743A (ja) 1995-12-27 1997-07-11 Oriental Yeast Co Ltd 可溶性ａｐｐの定量法
US6015662A (en) * 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
ZA97452B (en) * 1996-01-25 1997-08-15 Trinity College Dublin Streptococcus equi vaccine.
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
WO1997026913A1 (en) 1996-01-26 1997-07-31 The Trustees Of Columbia University In The City Of New York A POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID-β PEPTIDE
GB9602294D0 (en) * 1996-02-05 1996-04-03 Zeneca Ltd Heterocyclic compounds
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
JP2000505306A (ja) 1996-02-26 2000-05-09 モルフォシス・アクチェンゲゼルシャフト ２つまたはそれ以上の相互作用性（ポリ）ペプチドをコードする核酸配列の新規同定方法
US6150091A (en) * 1996-03-06 2000-11-21 Baylor College Of Medicine Direct molecular diagnosis of Friedreich ataxia
US5870587A (en) * 1996-03-20 1999-02-09 International Business Machines Corporation Information-handling system, method, and article of manufacture including a mechanism for providing an improved application binary interface
US6372225B1 (en) 1996-03-23 2002-04-16 The Research Foundation Of Microbial Diseases Of Osaka University Tetanus toxin functional fragment antigen and tetanus vaccine
HUP9902438A3 (en) * 1996-03-29 2000-03-28 Bayer Ag Parapoxvirus vectors
EP0954324A4 (de) * 1996-04-03 2000-11-02 Anergen Inc Impfstoffe enthaltend zyklische peptide zur behandlung und vorbeugung von diabetes
WO1997040147A1 (en) * 1996-04-19 1997-10-30 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Antigenically reactive regions of the hepatitis a virus polyprotein
US6284533B1 (en) * 1996-05-01 2001-09-04 Avant Immunotherapeutics, Inc. Plasmid-based vaccine for treating atherosclerosis
EP0938506B1 (de) 1996-07-16 2003-11-05 Plückthun, Andreas, Prof. Dr. Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit
CA2262006A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
CA2183901A1 (en) 1996-08-22 1998-02-23 Johanna E. Bergmann Targets for therapy and diagnosis of alzheimer's disease and down syndrome in humans
GB9617616D0 (en) 1996-08-22 1996-10-02 Osteometer Biotech As Assaying protein fragments in body fluids
EP1586584A1 (de) 1996-08-27 2005-10-19 Praecis Pharmaceuticals Incorporated beta-Amyloid Peptidaggregation regulierende Peptide mit D-Aminosäuren
US6057367A (en) * 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
US6797495B2 (en) * 1996-11-05 2004-09-28 The Regents Of The University Of California Somatic cells with ablated PrP gene and methods of use
US6022859A (en) * 1996-11-15 2000-02-08 Wisconsin Alumni Research Foundation Inhibitors of β-amyloid toxicity
WO1998022120A1 (en) 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
US6962984B2 (en) 1996-12-05 2005-11-08 Nihon University IgA nephropathy-related DNA
US20030068316A1 (en) 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US6218506B1 (en) * 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
CA2278547A1 (en) 1997-03-03 1998-09-11 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
US5798102A (en) 1997-03-04 1998-08-25 Milkhaus Laboratory, Inc. Treatment of cardiomyopathy
US6611610B1 (en) * 1997-04-02 2003-08-26 Gentex Corporation Vehicle lamp control
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
US20020086847A1 (en) * 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
NZ337765A (en) 1997-04-09 2001-09-28 Mindset Biopharmaceuticals Usa Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
HUP0001930A3 (en) 1997-04-15 2001-10-29 Pharmexa As Modified tnfalpha molecules, dna encoding such modified tnfalpha molecules and vaccines comprising such modified tnfalpha molecules and dna
US6787319B2 (en) * 1997-04-16 2004-09-07 American Home Products Corp. β-amyloid peptide-binding proteins and polynucleotides encoding the same
US5858205A (en) * 1997-05-13 1999-01-12 Uop Llc Multizone catalytic reforming process
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
AU740284B2 (en) 1997-06-13 2001-11-01 Genentech Inc. Stabilized antibody formulation
WO1999000150A2 (en) 1997-06-27 1999-01-07 Regents Of The University Of California Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
IT1293511B1 (it) 1997-07-30 1999-03-01 Gentili Ist Spa Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
JP2002501721A (ja) 1997-08-01 2002-01-22 モルフォシス・アクチェンゲゼルシャフト 多量体（ポリ）ペプチドコンプレックスのメンバーをコードする核酸配列を同定するための新規方法およびファージ
DE69842048D1 (de) 1997-08-01 2011-01-27 Max Planck Gesellschaft Zusammensetzung und verfahren zum nachweis von krankheiten in zusammenhang mit der bildung von amyloid-ähnlichen fibrillen oder protein-aggregaten
ATE435661T1 (de) 1997-08-29 2009-07-15 Antigenics Inc Adjuvant qs-21 enthaltende zusammensetzungen mit polysorbate oder cyclodextrin als hilfsmittel
US6175057B1 (en) * 1997-10-08 2001-01-16 The Regents Of The University Of California Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6913745B1 (en) * 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6743427B1 (en) * 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7588766B1 (en) * 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6710226B1 (en) * 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
DE1033998T1 (de) 1997-12-03 2001-05-23 Brigham And Women S Hospital B Methode zur unterdrückung von beta-amyloid-verwandten veränderungen in alzheimer
EP1036562A1 (de) 1997-12-03 2000-09-20 Fujisawa Pharmaceutical Co., Ltd. Arzneistoff in weicher pelletform sowie verfahren zu dessen herstellung
FR2777015B3 (fr) 1998-02-23 2000-09-15 Financ De Biotechnologie Procede et moyens pour l'obtention de modeles cellulaires et animaux de maladies neurodegeneratives
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US20050059591A1 (en) * 1998-04-07 2005-03-17 Neuralab Limited Prevention and treatment of amyloidogenic disease
ES2230848T3 (es) * 1998-04-28 2005-05-01 Smithkline Beecham Corporation Anticuerpos monoclonales con inmunogenicidad reducida.
NO314086B1 (no) 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
EP1080110A2 (de) 1998-05-19 2001-03-07 Yeda Research And Development Co. Ltd. Verwendung von aktivierten t zellen, nervensystem-spezifischen antigene zur behandlund von erkrankungen des nervensystems
AU4007599A (en) 1998-05-21 1999-12-06 University Of Tennessee Research Corporation, The Methods for amyloid removal using anti-amyloid antibodies
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6432710B1 (en) 1998-05-22 2002-08-13 Isolagen Technologies, Inc. Compositions for regenerating tissue that has deteriorated, and methods for using such compositions
US6710228B1 (en) * 1998-05-29 2004-03-23 Mycogen Corporation Cotton cells, plants, and seeds genetically engineered to express insecticidal and fungicidal chitin binding proteins (lectins)
US6727349B1 (en) 1998-07-23 2004-04-27 Millennium Pharmaceuticals, Inc. Recombinant anti-CCR2 antibodies and methods of use therefor
HUP0103976A3 (en) 1998-10-05 2008-04-28 Pharmexa As Novel methods for therapeutic vaccination
WO2000023082A1 (en) * 1998-10-19 2000-04-27 Yeda Research And Development Co. Ltd. Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
US7112661B1 (en) 1998-10-30 2006-09-26 The Research Foundation Of State University Of New York Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
CN101362518A (zh) 1999-01-19 2009-02-11 法玛西雅厄普约翰美国公司 γ-照射消毒的聚乙烯包装
JP2002535289A (ja) 1999-01-22 2002-10-22 ドウアリング，マシユー・ジヨン 神経疾患のワクチン媒介治療
US7629311B2 (en) 1999-02-24 2009-12-08 Edward Lewis Tobinick Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers
US7282570B2 (en) 1999-04-20 2007-10-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
IL146009A0 (en) 1999-05-05 2002-07-25 Neurochem Inc Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US6787637B1 (en) * 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
AR024558A1 (es) 1999-06-01 2002-10-16 Neuralab Ltd Composiciones del peptido a-beta y procesos para producir las mismas
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
EP1409654B1 (de) * 1999-06-16 2008-08-20 Boston Biomedical Research Institute Immunologische kontrolle des beta-amyloid gehaltes in vivo
CA2377382A1 (en) 1999-07-01 2001-01-11 Scios, Inc. Prevention and treatment of amyloid-associated disorders
IL147599A0 (en) 1999-07-15 2002-08-14 Genetics Inst Formulations for il-11
AU6524500A (en) 1999-08-04 2001-03-05 Northwestern University Amyloid beta protein (globular assembly and uses thereof)
US6919075B1 (en) 1999-09-03 2005-07-19 Ramot At Tel Aviv University Ltd. Bacteriophage displaying aβ epitopes and method of use
US6294171B2 (en) 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
US6824780B1 (en) 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
US20020094335A1 (en) 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
KR20080059676A (ko) 1999-11-29 2008-06-30 뉴로겜 인터내셔널 리미티드 알츠하이머 및 아밀로이드 관련 질병의 예방 및 치료용백신
WO2001042306A2 (en) 1999-12-08 2001-06-14 Mindset Biopharmaceuticals (Usa), Inc. Chimeric peptides (short b-cell epitope joined to a t-cell epitope) and their use for immunization
US6399314B1 (en) * 1999-12-29 2002-06-04 American Cyanamid Company Methods of detection of amyloidogenic proteins
ME00183B (me) 2000-02-21 2011-02-10 Pharmexa As Novi postupak za deregulaciju amiloida
CZ20022748A3 (cs) * 2000-02-21 2004-03-17 Pharmexa A/S Nová metoda regulace obsahu amyloidu
AU4178601A (en) 2000-02-24 2001-09-03 Univ Washington Humanized antibodies that sequester abeta peptide
US6294221B1 (en) * 2000-03-08 2001-09-25 E. I. Du Pont De Nemours And Company Process for spray-coating with frequent changes between aqueous and non-aqueous coating agents inside a spray-coating chamber
US6548840B1 (en) * 2000-04-03 2003-04-15 Hrl Laboratories, Llc Monolithic temperature compensation scheme for field effect transistor integrated circuits
CA2404237C (en) 2000-04-05 2010-01-26 University Of Tennessee Research Corporation Methods of investigating, diagnosing, and treating amyloidosis
DE60134499D1 (de) 2000-04-13 2008-07-31 Corixa Corp Immunostimulierende zusammnensetzungen die aminoalkyl glucosaminidephosphat und qs-21 enthalten
IL152625A0 (en) 2000-05-22 2003-06-24 Univ New York SYNTHETIC IMMUNOGENIC BUT NON-AMYLOIDOGENIC PEPTIDES HOMOLOGOUS TO AMYLOID beta FOR INDUCTION OF AN IMMUNE RESPONSE TO AMYLOID beta AND AMYLOID DEPOSITS
CA2414772C (en) 2000-07-07 2011-06-28 Jan Naslund Prevention and treatment of alzheimer's disease
US20020009445A1 (en) * 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
EP1172378A1 (de) 2000-07-12 2002-01-16 Richard Dr. Dodel Menschlische beta-Amyloid Antikörpern und ihre Verwendung zur Behandlung von Alzheimerscher Krankheit
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
ATE441663T1 (de) 2000-09-06 2009-09-15 Aventis Pharma Sa Verfahren und zusammensetzungen für amyloidosis- verbundene krankheiten
IT1319277B1 (it) 2000-10-24 2003-09-26 Chiesi Farma Spa Proteine di fusione utili per il trattamento di immunizzazione dellamalattia di alzheimer.
IL139308A0 (en) 2000-10-26 2001-11-25 Marikovsky Moshe Peptides from amyloid precursor protein which inhibit tumor growth and metastasis
DE60128138T2 (de) * 2000-11-02 2008-01-03 Cornell Research Foundation, Inc. In vivo multiphoton diagnostische detektion und bilddarstellung einer neurodegenerativen erkrankung
JP2004534511A (ja) * 2000-11-27 2004-11-18 プラエシス ファーマシューティカルズ インク． アミロイド形成性疾患を治療するための治療薬及びその使用法
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
AU2002246734A1 (en) * 2000-12-27 2002-08-12 University Of Texas Health Science Center Houston Prion isomers, methods of making, methods of using, and compositions and products comprising prion isomers
WO2002059621A2 (en) * 2001-01-24 2002-08-01 Bayer Corporation Regulation of transthyretin to treat obesity
EP1251138B1 (de) * 2001-04-19 2006-07-26 Hermann Dr. Schätzl Prion Proteindimere für Impfungen
DE60229051D1 (de) 2001-04-30 2008-11-06 Lilly Co Eli Humanisierte antikörper
WO2002088306A2 (en) 2001-04-30 2002-11-07 Eli Lilly And Company Humanized antibodies
US6524624B1 (en) * 2001-05-16 2003-02-25 Alcide Corporation Two-part disinfecting systems and compositions and methods related thereto
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US6888849B2 (en) * 2001-06-15 2005-05-03 Lucent Technologies Inc. Method for evaluating capacity utilization of a terminus in a communication system
WO2003000714A2 (en) 2001-06-22 2003-01-03 Panacea Pharmaceuticals, Inc. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
JP4317010B2 (ja) 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
US20030135035A1 (en) 2001-08-09 2003-07-17 Mark Shannon Human ZZAP1 protein
CA2451998A1 (en) 2001-08-17 2003-02-27 Eli Lilly And Company Anti-a.beta. antibodies
US20060073149A1 (en) 2001-08-17 2006-04-06 Bales Kelly R Rapid improvement of cognition in condition related to abeta
JP2005500389A (ja) 2001-08-17 2005-01-06 イーライ・リリー・アンド・カンパニー Ａβに関連する病態および疾患を治療するための、可溶性Ａβに高い親和性を有する抗体の使用
US20030082191A1 (en) 2001-08-29 2003-05-01 Poduslo Joseph F. Treatment for central nervous system disorders
WO2003022042A1 (en) * 2001-09-10 2003-03-20 Anticancer, Inc. Enhanced resolution of tumor metastasis
US6736142B2 (en) * 2001-09-13 2004-05-18 Gines Sanchez Gomez Protective tube and harness
US6907297B2 (en) 2001-09-28 2005-06-14 Ethicon, Inc. Expandable intracardiac return electrode and method of use
US6597198B2 (en) * 2001-10-05 2003-07-22 Intel Corporation Current mode bidirectional port with data channel used for synchronization
GB0124446D0 (en) * 2001-10-11 2001-12-05 Short Brothers Ltd Aircraft propulsive power unit
US7781413B2 (en) 2001-10-31 2010-08-24 Board Of Regents, The University Of Texas System SEMA3B inhibits tumor growth and induces apoptosis in cancer cells
DK1441589T3 (da) 2001-11-08 2012-08-06 Abbott Biotherapeutics Corp Stabil, flydende, farmaceutisk sammensætning af IgG-antistoffer
EP1572894B1 (de) * 2001-11-21 2016-04-13 New York University Zu amyloid-beta, prionprotein, amylin, alpha-synuclein oder polyglutaminwiederholungen homologe synthetische immunogene, jedoch keine ablagerungen bildende polypeptide und peptide zur induzierung einer immunreaktion dagegen
US20050227941A1 (en) 2001-12-17 2005-10-13 Karen Duff Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
DE60334364D1 (de) 2002-02-21 2010-11-11 Univ California Behandlungsverfahren unter verwendung von anti-cd22-antikörpern
US6688651B2 (en) * 2002-02-21 2004-02-10 Dmt Co., Ltd. Device for locking cap nut for coupling
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
CA2390700C (en) * 2002-06-11 2004-09-07 Henry Tsang Illuminated soap bar with sound
GB0213437D0 (en) 2002-06-12 2002-07-24 Univ Cranfield Temporary tattoos: A novel vehicle for skin testing
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US6892535B2 (en) * 2002-06-14 2005-05-17 Volvo Construction Equipment Holding Sweden Ab Hydraulic circuit for boom cylinder combination having float function
DE60336902D1 (de) 2002-07-19 2011-06-09 Cytos Biotechnology Ag Impfstoffzusammensetzungen enthaltende amyloid beta 1-6 antigenarrays
WO2004013172A2 (en) 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
AU2003279728B2 (en) 2002-10-01 2007-09-27 Northwestern University Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof
US20040080762A1 (en) * 2002-10-25 2004-04-29 Xerox Corporation Half-tone based enhancement of black
US20060019850A1 (en) * 2002-10-31 2006-01-26 Korzenski Michael B Removal of particle contamination on a patterned silicon/silicon dioxide using dense fluid/chemical formulations
FR2846667B1 (fr) 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
US6787129B1 (en) 2003-01-13 2004-09-07 Zenitech Llc Castor polyester as gloss agents in anionic systems
KR20050118669A (ko) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 가용성 ａ-베타에 대한 항체를 생성하기 위한 능동 면역화
WO2004071408A2 (en) 2003-02-10 2004-08-26 Applied Molecular Evolution, Inc. Aβ BINDING MOLECULES
PT1610820E (pt) 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
EP1480041A1 (de) 2003-05-22 2004-11-24 Innogenetics N.V. Verfahren zur Voraussage, zur Diagnose und zur vergleichenden Diagnose von Alzheimer
TWI306458B (en) * 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US20060182321A1 (en) 2003-07-07 2006-08-17 Agency For Science, Technology And Research Method and apparatus for extracting third ventricle information
WO2005014041A2 (en) 2003-07-24 2005-02-17 Novartis Ag Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases
WO2005026211A2 (en) 2003-09-05 2005-03-24 Eli Lilly And Company Anti-ghrelin antibodies
CA2445743A1 (en) 2003-10-08 2005-04-08 The University Of British Columbia Methods for modulating neuronal responses
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
EP2479184A3 (de) 2003-12-17 2013-09-04 Janssen Alzheimer Immunotherapy Beta-Immunogen-Peptidträgerkonjugate und Herstellungsverfahren dafür
SG149013A1 (en) 2003-12-17 2009-01-29 Wyeth Corp Immunogenic peptide carrier conjugates and methods of producing same
US20050214222A1 (en) 2004-02-13 2005-09-29 Mckinnon Stuart J In vivo imaging of amyloid plaques in glaucoma using intravenous injectable dyes
EP3112352B1 (de) 2004-03-15 2018-11-21 Janssen Pharmaceutica NV Opioid-rezeptor-modulatoren
DK1771208T3 (da) 2004-07-02 2013-09-02 Univ Pittsburgh Anvendelse af thioflavin radiomarkerede derivater i amyloid billeddannelse til vurdering af anti-amyloide terapier
EA016357B1 (ru) 2004-07-30 2012-04-30 Ринат Ньюросайенс Корп. Антитела, направленные против бета-амилоидного пептида, и способы их применения
US7328838B2 (en) * 2004-09-09 2008-02-12 Igt Counterfeit cashless instrument detection methods and systems
PE20060817A1 (es) 2004-09-10 2006-10-10 Wyeth Corp Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
WO2006042158A2 (en) 2004-10-05 2006-04-20 Wyeth Methods and compositions for improving recombinant protein production
US20060160161A1 (en) 2004-10-26 2006-07-20 Elan Pharmaceuticals, Inc. Methods for assessing antibodies to neurodegenerative disease-associated antigens
US20060026911A1 (en) * 2004-11-18 2006-02-09 Sutton Adam F Footer track with moisture vent
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
WO2006066118A2 (en) 2004-12-15 2006-06-22 Neuralab Limited Contextual fear test for predicting efficacy of alzheimer immunotherapeutic treatment
AR051800A1 (es) 2004-12-15 2007-02-07 Wyeth Corp Anticuerpos a beta usados en mejorar la cognicion
US20060240486A1 (en) 2004-12-15 2006-10-26 Johnson-Wood Kelly L Immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
KR20070107079A (ko) 2005-01-28 2007-11-06 와이어쓰 안정화된 액체 폴리펩타이드 제형
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
CN101171031B (zh) 2005-05-05 2011-09-28 默沙东公司 防止和治疗阿尔茨海默病的肽偶联物组合物和方法
EP2388274A1 (de) 2005-06-17 2011-11-23 Janssen Alzheimer Immunotherapy Verfahren zur Reinigung von Anti-A-Beta-Antikörpern
AU2006270084B2 (en) 2005-07-18 2011-08-25 Merck Sharp & Dohme Corp. Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
CN101558080A (zh) * 2005-11-10 2009-10-14 罗斯坎普研究有限责任公司 Aβ肽片段对血管生成的调节
NZ571038A (en) 2006-03-30 2011-03-31 Glaxo Group Ltd Antibodies against amyloid-beta peptide
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2010044803A1 (en) 2008-10-17 2010-04-22 Elan Pharma International Limited Treatment of amyloidogenic diseases
WO2008011348A2 (en) 2006-07-14 2008-01-24 Ac Immune S.A. Humanized antibody against amyloid beta
JP2010521651A (ja) 2007-03-12 2010-06-24 独立行政法人放射線医学総合研究所 脳内のアミロイド関連神経炎症の画像化
KR20100016661A (ko) * 2007-04-18 2010-02-12 얀센 알츠하이머 이뮤노테라피 대뇌 아밀로이드 혈관병증의 예방 및 치료
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP2182983B1 (de) 2007-07-27 2014-05-21 Janssen Alzheimer Immunotherapy Behandlung von amyloidogenen erkrankungen mittels humanisierter anti-abeta antikörper
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2011133919A1 (en) 2010-04-22 2011-10-27 Janssen Alzheimer Immunotherapy Use of tau to monitor immunotherapy
PT2237803E (pt) * 2007-12-28 2015-10-16 Prothena Biosciences Ltd Tratamento e profilaxia da amiloidose
KR20160135843A (ko) 2008-09-18 2016-11-28 세다르스-신나이 메디칼 센터 알츠하이머병의 검출을 위한 광학적 방법
EP2538982A4 (de) 2010-02-25 2016-02-17 Janssen Alzheimer Immunotherap Pet-überwachung einer auf a-beta gezielten immuntherapie

Also Published As

Publication number Publication date
US20050249725A1 (en) 2005-11-10
DE69840969D1 (de) 2009-08-20
AU1706199A (en) 1999-06-16
SG111083A1 (en) 2005-05-30
US20130058869A1 (en) 2013-03-07
PT1994937E (pt) 2011-02-22
HRP20000443A2 (en) 2000-10-31
JP4677333B2 (ja) 2011-04-27
KR20090078366A (ko) 2009-07-17
SI1994937T1 (sl) 2011-04-29
HU228061B1 (en) 2012-09-28
CN1281366A (zh) 2001-01-24
NZ504569A (en) 2005-01-28
US8034339B2 (en) 2011-10-11
DK2305282T3 (da) 2013-10-07
ID25504A (id) 2000-10-05
PT1679080E (pt) 2009-09-10
IL136252A (en) 2010-11-30
EA200000608A1 (ru) 2000-12-25
ATE433760T1 (de) 2009-07-15
NO328865B1 (no) 2010-06-07
ES2263408T3 (es) 2009-11-16
KR20010032635A (ko) 2001-04-25
US8535673B2 (en) 2013-09-17
US20080227718A1 (en) 2008-09-18
EP2305282A3 (de) 2011-05-18
NO20002784L (no) 2000-07-31
US20140227274A1 (en) 2014-08-14
IL136252A0 (en) 2001-05-20
DE06075479T1 (de) 2006-11-16
EA200401473A1 (ru) 2005-04-28
US20040228865A1 (en) 2004-11-18
US20050196399A1 (en) 2005-09-08
IL193245A0 (en) 2009-09-22
IS5500A (is) 2000-05-17
US6982084B2 (en) 2006-01-03
DK1994937T3 (da) 2011-02-07
CY1111370T1 (el) 2015-08-05
US6972127B2 (en) 2005-12-06
NO331425B1 (no) 2011-12-27
US8034348B2 (en) 2011-10-11
ES2310017T3 (es) 2008-12-16
MY134906A (en) 2007-12-31
US20050191292A1 (en) 2005-09-01
TWI239847B (en) 2005-09-21
US20080227719A1 (en) 2008-09-18
CA2312920C (en) 2016-07-12
AR020050A1 (es) 2002-04-10
KR101248711B1 (ko) 2013-03-28
EP1690547A1 (de) 2006-08-16
JP2006077030A (ja) 2006-03-23
HK1095265A1 (en) 2007-05-04
WO1999027944A1 (en) 1999-06-10
CO4980846A1 (es) 2000-11-27
EP1033996B1 (de) 2008-06-25
EP1690547B1 (de) 2009-07-08
DE69842082D1 (de) 2011-02-10
CA2312920A1 (en) 1999-06-10
DE69839647D1 (de) 2008-08-07
NO20092874L (no) 2000-07-31
CN100374151C (zh) 2008-03-12
US20050031629A1 (en) 2005-02-10
PT2305282E (pt) 2013-09-27
HK1094535A1 (en) 2007-04-04
IL205298A0 (en) 2011-07-31
GEP20043319B (en) 2004-05-10
NO20002784D0 (no) 2000-05-31
CZ303137B6 (cs) 2012-04-25
US20050048049A1 (en) 2005-03-03
JP4677094B2 (ja) 2011-04-27
DE1033996T1 (de) 2001-06-07
SI1679080T1 (sl) 2009-12-31
PL202698B1 (pl) 2009-07-31
KR20120135915A (ko) 2012-12-17
EP1033996A1 (de) 2000-09-13
TR200001608T2 (tr) 2001-07-23
CZ20001706A3 (cs) 2000-11-15
IL191904A0 (en) 2008-12-29
JP2006131639A (ja) 2006-05-25
US20050249727A1 (en) 2005-11-10
EA007218B1 (ru) 2006-08-25
EP2305282A2 (de) 2011-04-06
IL191904A (en) 2014-05-28
HUP0100627A3 (en) 2006-03-28
SI1033996T1 (sl) 2009-02-28
NO20100061L (no) 2000-07-31
US20090191231A1 (en) 2009-07-30
JP2002502802A (ja) 2002-01-29
NO332813B1 (no) 2013-01-21
US20060029611A1 (en) 2006-02-09
ES2428740T3 (es) 2013-11-11
EP2305282B1 (de) 2013-07-10
PL202706B1 (pl) 2009-07-31
US8642044B2 (en) 2014-02-04
JP4677334B2 (ja) 2011-04-27
US20040171816A1 (en) 2004-09-02
HRP20090568A2 (hr) 2010-06-30
GEP20053715B (en) 2005-12-26
HRP20000443B1 (en) 2009-11-30
KR100936419B1 (ko) 2010-01-12
DK1679080T3 (da) 2009-09-28
CY1108331T1 (el) 2014-02-12
DK1033996T3 (da) 2008-09-22
HU228493B1 (en) 2013-03-28
EA009283B1 (ru) 2007-12-28
BR9815357A (pt) 2000-10-24
WO1999027944A9 (en) 1999-09-23
US20060034858A1 (en) 2006-02-16
ATE399016T1 (de) 2008-07-15
US20080096818A1 (en) 2008-04-24
US20050163788A1 (en) 2005-07-28
US7014855B2 (en) 2006-03-21
US20050013815A1 (en) 2005-01-20
EP1994937B1 (de) 2010-12-29
US20050037026A1 (en) 2005-02-17
ES2262460T1 (es) 2006-12-01
BG104562A (en) 2001-01-31
EA200601132A1 (ru) 2007-02-27
ES2263408T1 (es) 2006-12-16
SA99191269B1 (ar) 2006-03-15
SI2305282T1 (sl) 2013-10-30
EP1994937A3 (de) 2008-12-24
US20050019330A1 (en) 2005-01-27
US20050191314A1 (en) 2005-09-01
PT1033996E (pt) 2008-10-02
PE20001383A1 (es) 2000-11-25
HUP0100627A1 (hu) 2001-06-28
ATE435659T1 (de) 2009-07-15
US6946135B2 (en) 2005-09-20
EP1679080B1 (de) 2009-06-17
US20050142132A1 (en) 2005-06-30
JP2010215651A (ja) 2010-09-30
US20050019343A1 (en) 2005-01-27
EP1994937A2 (de) 2008-11-26
US20040171815A1 (en) 2004-09-02
PL342649A1 (en) 2001-06-18
EE200000379A (et) 2001-04-16
US20120276116A1 (en) 2012-11-01
ATE493149T1 (de) 2011-01-15
DE69840922D1 (de) 2009-07-30
US6808712B2 (en) 2004-10-26
CY1109368T1 (el) 2014-07-02
EP1033996A4 (de) 2004-05-26
US20040170641A1 (en) 2004-09-02
EP1679080A2 (de) 2006-07-12
EP1679080A3 (de) 2006-07-19
EE05377B1 (et) 2011-02-15

Similar Documents

Publication Publication Date Title
DE06075704T1 (de) Vorbeugung und Behandlung von amyloidogener Krankheit
Misidou et al. Complex regional pain syndrome: an update
Espir et al. Treatment of paroxysmal disorders in multiple sclerosis with carbamazepine (Tegretol)
Alldredge et al. Status epilepticus related to alcohol abuse
NO931267D0 (no) Fremgangsmaate for behandling eller forebyggelse av type 1diabetes ved oral administrering av insulin
KR20150003765A (ko) 라퀴니모드와 디메틸 푸마레이트의 병용물에 의한 다발성 경화증의 치료
JPS58121213A (ja) アルツハイマ−病治療剤
Smith Clinical recommendations for oxcarbazepine
HUE027236T2 (en) Methods for Adhesive Capsulitis Treatment
DE04702967T1 (de) Behandlung von benigner prostatahyperplasie
Mikkelsen et al. Prophylactic treatment of migraine with tolfenamic acid, propranolol and placebo
JPH05194209A (ja) 血管内皮細胞機能改善剤
JP2007523121A (ja) 血管性鬱病の処置のためのコリンエステラーゼ阻害剤の使用
Gerolami et al. Controlled trial of chenodeoxycholic therapy for radiolucent gallstones: A multicenter study
EP3296316A1 (de) Peptide zur behandlung und frühdiagnose von morbus alzheimer und anderer tauopathien
Slim et al. The incidence of phlebitis with intravenous amiodarone at guideline dose recommendations.
AU2002334001B2 (en) Use of ginkgo biloba extracts for preparing a medicine for treating sarcopenia
Kaye Clinical experiences with, and pharmacokinetics of, oxamniquine
EP0331014A2 (de) Verwendung von ACE-Inhibitoren für die Diabetesprophylaxe
Thorpe et al. The role of an antidepressant, dibenzepin (Noveril), in the relief of pain in chronic arthritic states
Snyder Male reproductive aging
Amsterdam et al. Double-blind, placebo-controlled, fixed dose trial of minaprine in patients with major depression
De Keyser et al. Treatment of acute relapses in multiple sclerosis at home with oral dexamethasone: a pilot study
Sandercock Antiplatelet therapy with aspirin in acute ischaemic stroke
DE2454870C3 (de) Therapeutischer Impfstoff zur Vorbeugung gegen Gefäßerkrankungen und deren Behandlung